Altitude
The Day After Approval: Which States Will Let Doctors Prescribe Psilocybin
Policy

The Day After Approval: Which States Will Let Doctors Prescribe Psilocybin

Two psilocybin applications are about to sit in front of the FDA at once. Whether a patient in your state can get one depends on a federal scheduling rule, a state drug law most people have never read, and in five states, two words lifted from a patent.

Nathan Richardson • Nov 9, 2026

FDA approval of psilocybin won't make it legal everywhere overnight. Here's how the federal scheduling step works, which states have "trigger laws" that switch on automatically, which will need new legislation in 2027, and why "crystalline polymorph" could matter now that Usona has filed.

Compass Pathways says its psilocybin application will be complete within days. Usona Institute filed its own on Nov. 2. Both carry National Priority Vouchers, which can shrink the FDA's review to one or two months, so a first approval in early 2027 is now a realistic scenario rather than a hopeful one. (Both programs are on our trials tracker.)

That raises a question people are already typing into search engines: does a state's law automatically change once the FDA says yes? The short answer is no in most places, and yes in a handful that planned for it.

Step one is federal, and it isn't the FDA

FDA approval alone doesn't produce a prescription. Psilocybin sits in Schedule I of the Controlled Substances Act, and under federal law, approval of a drug the government intends to control "shall not take effect until the interim final rule controlling the drug is issued" by the DEA. A 2015 law gives the DEA 90 days to issue that rule, but only when the Department of Health and Human Services recommends Schedule II through V.

Regulatory scientist Odette Hauke, a former regulatory affairs director at AtaiBeckley, points out in an October column for Psychedelic State(s) of America that the most likely outcome is narrow. The approved product would move to a lower schedule while psilocybin itself stays in Schedule I. Compass's own base case is Schedule III for its product. A narrow federal carve-out is good for patients getting the drug in a clinic and changes nothing for mushrooms.

Step two is your state, and states handle it three ways

Every state has its own controlled substances law, and a federal change doesn't rewrite it. Hauke reviewed ten of them and found three patterns:

  • Follows federal changes automatically: Oregon, Washington and Missouri. Washington and Missouri give a state agency 30 days to object.
  • Needs a state agency to act: Massachusetts, Ohio, Virginia and Wisconsin. That can be slow. Wisconsin's pharmacy board took 667 days after FDA approval to schedule the postpartum depression drug zuranolone.
  • Needs the legislature: Colorado and Iowa. Minnesota's board can issue only a temporary order, good for 12 months, before lawmakers have to act.

That's ten states out of fifty, so it's a sample, not a map. (We covered the other federal threads, including ICER's cost review of COMP360 and a bill to move scheduling from the DEA to HHS, in our post-election roundup.) But it shows why a group of states passed laws in advance.

The trigger-law states

A trigger law tells the state, ahead of time, what to do once the FDA approves and the DEA reschedules. These are the ones enacted so far, per UC Berkeley's Center for the Science of Psychedelics policy map and state legislative records:

StateLawCoversStatus
ColoradoHB25-1063, then SB26-031First "crystalline polymorph" psilocybin; now any FDA-approved Schedule I drug, natural medicine excludedSigned 2025 and April 2026
VirginiaHB 1347 / SB 379Any FDA-approved psilocybin formulation given by a health professional in a health care settingSigned April 2026
ArizonaSB 1555Crystalline polymorph psilocybin; lapses if not approved and rescheduled by Jan. 1, 2031Signed 2025
GeorgiaHB 382Crystalline polymorph psilocybinEnacted May 2026
South DakotaHB 1099Crystalline polymorph psilocybin, into Schedule IVSigned March 2026
West VirginiaSB 906Crystalline polymorph psilocybinLaw April 2026
MississippiSB 2056Crystalline polymorph psilocybinPassed 2026

Iowa came close. Its bill passed 92–0 and 47–0 before Gov. Kim Reynolds vetoed it in June 2025, saying it "surrenders state authority to make an informed determination about classification to federal officials at the FDA." Bills are pending or were introduced this year in Kansas, Pennsylvania, New Mexico and Rhode Island. Kansas's was Compass's own bill, and our scorecard of the 2026 session tracks the rest.

None of these laws touches mushrooms, decriminalization or the state-run programs in Oregon and Colorado. Each one covers a prescription product, in a clinic, after federal action.

Two words from a patent

Most of those laws don't say "psilocybin." They say "crystalline polymorph psilocybin," and that phrase has a history. Psychedelic Alpha's Josh Hardman reported in January 2025 that Compass was lobbying for these narrowly written bills; its advocacy manager testified for Colorado's. Compass's patents cover a specific crystal form of psilocybin it calls Polymorph A, which we covered in our psilocybin patent deep dive. "Crystalline polymorph psilocybin isn't scientific language — it's a patent portfolio or marketing term for COMP360," Shahin Shams of the nonprofit Porta Sophia told The Microdose.

That mattered less when Compass was alone. It matters now that Usona has filed. Would Usona's psilocybin count as a "crystalline polymorph" under these laws? Nobody has tested it. Usona's chemists have published their own crystal-structure work arguing that pharmaceutical psilocybin samples fall into a few known forms, and that some patented "novel" forms aren't novel. A rival company argued in 2025 that any recrystallized psilocybin would qualify. Until a regulator or court reads the statute, patients in five states could find that one approved psilocybin is legal and the other is in limbo.

Virginia shows the alternative. In 2025, then-Gov. Glenn Youngkin vetoed a polymorph-only bill. This year, Gov. Abigail Spanberger signed one that covers any FDA-approved formulation given in a health care setting, and it says the pharmacy board "shall" reschedule, not "may." Colorado went further still: its 2026 law covers any FDA-approved Schedule I drug, which would include MDMA if Resilient's refiled application wins approval.

What to watch

  • The HHS scheduling recommendation. Whether it names Schedule II through V decides whether the DEA's 90-day clock runs at all.
  • Pharmacy board calendars in Virginia and other states that need an agency to act. Virginia's law ties action to the board's next quarterly meeting after a 30-day wait.
  • 2027 legislative sessions in states that need a bill, including Iowa again and Minnesota. Iowa's next attempt will land on the desk of Democrat Rob Sand, who won the Nov. 3 governor's race over a MAHA-backed Republican, rather than Reynolds. Our midterms breakdown covers the rest of the new map.
  • A rewrite of the federal rules. Rep. Steve Cohen (D-TN) introduced a bill on Oct. 29 that would move most scheduling decisions from the DEA to HHS. MAPS has endorsed it. Cohen is retiring and the bill isn't expected to move this year, but it's a marker for the next Congress.
  • Congress. The PATH Caucus's October report, drawn from its 2024 request for information, made federal-state coordination its central theme, with recommendations on provider credentialing and a national adverse-event monitoring system.

We'll update this as approvals and rulings land. Our intelligence hub tracks the companies and programs involved.

This article is for information only and isn't legal or medical advice. Psilocybin remains a Schedule I substance under federal law and is illegal in most states outside approved research and state programs. Laws change quickly; check your state's current statutes or a licensed attorney before acting on anything here.

Sources

← Back to Journal